{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T13:14:22Z","timestamp":1789910062781,"version":"4.0.1"},"reference-count":30,"publisher":"WHO Press","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Bull. World Health Organ."],"published-print":{"date-parts":[[2014,1,1]]},"DOI":"10.2471\/blt.13.122028","type":"journal-article","created":{"date-parts":[[2014,4,7]],"date-time":"2014-04-07T12:05:46Z","timestamp":1396872346000},"page":"68-74","source":"Crossref","is-referenced-by-count":60,"title":["Principles for designing future regimens for multidrug-resistant tuberculosis"],"prefix":"10.2471","volume":"92","author":[{"given":"Grania","family":"Brigden","sequence":"first","affiliation":[{"name":"Access Campaign, M\u00e9decins Sans Fronti\u00e8res, 78 Rue de Lausanne, PO Box 116, Geneva, CH1211, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bern-Thomas","family":"Nyang\u2019wa","sequence":"additional","affiliation":[{"name":"M\u00e9decins Sans Fronti\u00e8res, London, England."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"du Cros","sequence":"additional","affiliation":[{"name":"M\u00e9decins Sans Fronti\u00e8res, London, England."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis","family":"Varaine","sequence":"additional","affiliation":[{"name":"M\u00e9decins Sans Fronti\u00e8res, Paris, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Hughes","sequence":"additional","affiliation":[{"name":"M\u00e9decins Sans Fronti\u00e8res, Cape Town, South Africa."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Rich","sequence":"additional","affiliation":[{"name":"Partners in Health, Boston, United States of America (USA)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"C Robert","family":"Horsburgh","sequence":"additional","affiliation":[{"name":"Boston University School of Public Health, Boston, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carole D","family":"Mitnick","sequence":"additional","affiliation":[{"name":"Department of Global Health and Social Medicine, Harvard Medical School, Boston, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Nuermberger","sequence":"additional","affiliation":[{"name":"Center for Tuberculosis Research, Johns Hopkins University, Baltimore, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"McIlleron","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology, University of Cape Town, Cape Town, South Africa."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick PJ","family":"Phillips","sequence":"additional","affiliation":[{"name":"Medical Research Council Clinical Trials Unit, London, England."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manica","family":"Balasegaram","sequence":"additional","affiliation":[{"name":"Access Campaign, M\u00e9decins Sans Fronti\u00e8res, 78 Rue de Lausanne, PO Box 116, Geneva, CH1211, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1305","published-online":{"date-parts":[[2013,10,25]]},"reference":[{"key":"key-10.2471\/BLT.13.122028-201404071433-R1","unstructured":"World Health Organization [Internet]. WHO global tuberculosis report 2012. Geneva: WHO; 2012. Available from: http:\/\/apps.who.int\/iris\/bitstream\/10665\/75938\/1\/9789241564502_eng.pdf [accessed 29 September 2013]."},{"key":"key-10.2471\/BLT.13.122028-201404071433-R2","unstructured":"Guidelines for the programmatic management of drug-resistant tuberculosis 2011 update. Geneva: World Health Organization; 2011 (WHO\/HTM\/TB\/2011.6). Available from: http:\/\/apps.who.int\/iris\/bitstream\/10665\/44597\/1\/9789241501583_eng.pdf [accessed 29 September 2013]."},{"key":"key-10.2471\/BLT.13.122028-201404071433-R3","unstructured":"DR-TB drugs under the microscope: sources and prices for drug resistant TB medications. 2nd ed. Geneva: M\u00e9decins Sans Fronti\u00e8res & International Union Against Tuberculosis and Lung Disease; 2012."},{"key":"key-10.2471\/BLT.13.122028-201404071433-R4","doi-asserted-by":"publisher","first-page":"e1001300","DOI":"10.1371\/journal.pmed.1001300","article-title":"Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients.","volume":"9","author":"Ahuja","year":"2012","journal-title":"PLoS Med"},{"key":"key-10.2471\/BLT.13.122028-201404071433-R5","unstructured":"World Health Organization [Internet]. The use of bedaquiline in the treatment of multidrug-resistant tuberculosis. Interim policy guidance. Geneva: WHO; 2013. Available from: http:\/\/www.who.int\/iris\/bitstream\/10665\/84879\/1\/9789241505482_eng.pdf [accessed 23 August 2013]."},{"key":"key-10.2471\/BLT.13.122028-201404071433-R6","unstructured":"Otsuka receives opinion from CHMP on delamanid. Geneva: Otsuka Pharmaceutical Co., Ltd.; 2013. Available from: http:\/\/www.otsuka.co.jp\/en\/company\/release\/2013\/0726_01.html [accessed 23 August 2013]."},{"key":"key-10.2471\/BLT.13.122028-201404071433-R7","unstructured":"European Medicines Agency [Internet]. Refusal of the marketing authorisation for delamanid (delamanid).London: EMA; 2013. Available from: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Summary_of_opinion_-_Initial_authorisation\/human\/002552\/WC500146651.pdf [accessed 14 October 2013]."},{"key":"key-10.2471\/BLT.13.122028-201404071433-R8","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.5588\/ijtld.12.0144","article-title":"Systematic review of clofazimine for the treatment of drug-resistant tuberculosis [review].","volume":"17","author":"Gopal","year":"2013","journal-title":"Int J Tuberc Lung Dis"},{"key":"key-10.2471\/BLT.13.122028-201404071433-R9","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1056\/NEJMoa1201964","article-title":"Linezolid for treatment of chronic extensively drug-resistant tuberculosis.","volume":"367","author":"Lee","year":"2012","journal-title":"N Engl J Med"},{"key":"key-10.2471\/BLT.13.122028-201404071433-R10","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1093\/jac\/dks389","article-title":"Outcomes of clofazimine for the treatment of drug-resistant tuberculosis: a systematic review and meta-analysis.","volume":"68","author":"Dey","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"key-10.2471\/BLT.13.122028-201404071433-R11","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/S0140-6736(12)61080-0","article-title":"14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial.","volume":"380","author":"Diacon","year":"2012","journal-title":"Lancet"},{"key":"key-10.2471\/BLT.13.122028-201404071433-R12","doi-asserted-by":"publisher","first-page":"3114","DOI":"10.1128\/AAC.00384-12","article-title":"Sterilizing activities of novel combinations lacking first- and second-line drugs in a murine model of tuberculosis.","volume":"56","author":"Williams","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"key-10.2471\/BLT.13.122028-201404071433-R13","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.1056\/NEJMoa0808427","article-title":"The diarylquinoline TMC207 for multidrug-resistant tuberculosis.","volume":"360","author":"Diacon","year":"2009","journal-title":"N Engl J Med"},{"key":"key-10.2471\/BLT.13.122028-201404071433-R14","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1056\/NEJMoa1112433","article-title":"Delamanid for multidrug-resistant pulmonary tuberculosis.","volume":"366","author":"Gler","year":"2012","journal-title":"N Engl J Med"},{"key":"key-10.2471\/BLT.13.122028-201404071433-R15","doi-asserted-by":"publisher","first-page":"e30479","DOI":"10.1371\/journal.pone.0030479","article-title":"Rapid evaluation in whole blood culture of regimens for XDR-TB containing PNU-100480 (sutezolid), TMC207, PA-824, SQ109, and pyrazinamide.","volume":"7","author":"Wallis","year":"2012","journal-title":"PLoS One"},{"key":"key-10.2471\/BLT.13.122028-201404071433-R16","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1016\/S0140-6736(12)60734-X","article-title":"Prevalence of and risk factors for resistance to second-line drugs in people with multidrug-resistant tuberculosis in eight countries: a prospective cohort study.","volume":"380","author":"Dalton","year":"2012","journal-title":"Lancet"},{"key":"key-10.2471\/BLT.13.122028-201404071433-R17","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/S0140-6736(13)60341-4","article-title":"Resistance to second-line drugs in multidrug-resistant tuberculosis.","volume":"381","author":"Nyang\u2019wa","year":"2013","journal-title":"Lancet"},{"key":"key-10.2471\/BLT.13.122028-201404071433-R18","first-page":"117","article-title":"Resultados obtenidos mediante reg\u00edmentes de asociacion con dos o tres drogas secundarias en el retratamiento del tuberculoso pulmonar cr\u00f3nico.","volume":"109","author":"De March Ayuela","year":"1968","journal-title":"Rev Clin Esp"},{"key":"key-10.2471\/BLT.13.122028-201404071433-R19","first-page":"829","article-title":"Treatment of multidrug-resistant tuberculosis: evidence and controversies.","volume":"10","author":"Caminero","year":"2006","journal-title":"Int J Tuberc Lung Dis"},{"key":"key-10.2471\/BLT.13.122028-201404071433-R20","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1164\/rccm.201001-0077OC","article-title":"Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis.","volume":"182","author":"Van Deun","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"key-10.2471\/BLT.13.122028-201404071433-R21","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1016\/S0140-6736(12)60734-X","article-title":"Prevalence of and risk factors for resistance to second-line drugs in people with multidrug-resistant tuberculosis in eight countries: a prospective cohort study.","volume":"380","author":"Dalton","year":"2012","journal-title":"Lancet"},{"key":"key-10.2471\/BLT.13.122028-201404071433-R22","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1093\/jac\/dkr221","article-title":"Multidrug-resistant tuberculosis (MDR-TB) treatment in the UK: a study of injectable use and toxicity in practice.","volume":"66","author":"Sturdy","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"key-10.2471\/BLT.13.122028-201404071433-R23","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/1472-6815-7-5","article-title":"Audiologic monitoring of multi-drug resistant tuberculosis patients on aminoglycoside treatment with long term follow-up.","volume":"7","author":"Duggal","year":"2007","journal-title":"BMC Ear Nose Throat Disord"},{"key":"key-10.2471\/BLT.13.122028-201404071433-R24","first-page":"1382","article-title":"Adverse events in the treatment of multidrug-resistant tuberculosis: results from the DOTS-Plus initiative.","volume":"8","author":"Nathanson","year":"2004","journal-title":"Int J Tuberc Lung Dis"},{"key":"key-10.2471\/BLT.13.122028-201404071433-R25","first-page":"1373","article-title":"Side effects associated with the treatment of multidrug-resistant tuberculosis.","volume":"9","author":"T\u00f6r\u00fcn","year":"2005","journal-title":"Int J Tuberc Lung Dis"},{"key":"key-10.2471\/BLT.13.122028-201404071433-R26","doi-asserted-by":"publisher","DOI":"10.1007\/s12013-013-9589-5","article-title":"Clinical benefit of delamanid (OPC-67683) in the treatment of multidrug-resistant tuberculosis patients in China.","author":"Zhang","year":"2013","journal-title":"Cell Biochem Biophys"},{"key":"key-10.2471\/BLT.13.122028-201404071433-R27","unstructured":"Highlights of prescribing information. Silver Spring: United States Food and Drug Agency; 2012. Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/204384s000lbl.pdf [accessed 23 August 2013]."},{"key":"key-10.2471\/BLT.13.122028-201404071433-R28","doi-asserted-by":"publisher","first-page":"CD001362","DOI":"10.1002\/14651858.CD001362","article-title":"Regimens of less than six months for treating tuberculosis.","author":"Gelband","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"key":"key-10.2471\/BLT.13.122028-201404071433-R29","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1183\/09031936.00125812","article-title":"Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis.","volume":"41","author":"Skripconoka","year":"2013","journal-title":"Eur Respir J"},{"key":"key-10.2471\/BLT.13.122028-201404071433-R30","unstructured":"World Health Organization [Internet]. WHO model list of essential medicines application\u2013Bedaquiline 100 mg tablet. Geneva: WHO; 2013. Available from: http:\/\/www.who.int\/selection_medicines\/committees\/expert\/19\/applications\/Bedaquiline_6_2_4_A_Ad.pdf [accessed 29 September 2013]."}],"container-title":["Bulletin of the World Health Organization"],"original-title":[],"deposited":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T17:12:49Z","timestamp":1742404369000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3865549\/pdf\/BLT.13.122028.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10,25]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2013,10,25]]},"published-print":{"date-parts":[[2014,1,1]]}},"URL":"https:\/\/doi.org\/10.2471\/blt.13.122028","relation":{},"ISSN":["0042-9686"],"issn-type":[{"value":"0042-9686","type":"print"}],"subject":[],"published":{"date-parts":[[2013,10,25]]}}}